The Insides Company
MedTech company providing medical devices for intestinal failure.
The Insides Company is a first-in-class medtech company, providing therapeutic devices for patients with intestinal failure.
The company’s medical devices are life-saving and reduce treatment costs by $290K per patient.
Quarter-on-quarter revenue growth from sales to a distribution network servicing 25 countries in EMEA and APAC.
Seeking the last $1M of a $5M raise, having already raised $4.0M on an $17.2M pre-money. Will consider oversubscriptions for the right investor.
On track to serving patients in 50+ countries and dominating the $4.4B (pa) market opportunity the company is creating.
Problem and Solution
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a. Nullam fringilla diam eget dui placerat fermentu
Open an account to get
access to more details
Market Opportunity
Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.
Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.
Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.
Aenean
Open an account to get
access to more details
Competitive Advantage
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem
Open an account to get
access to more details
Highlights & Milestones
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a. Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pha
Open an account to get
access to more details
See more exiting opportunities on CapitalHQ
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...
ProxyTwin
ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...
HorizonTwo Capital Partners
HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.
The Insides Company
First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.
DCARB
We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.
Grabba Technologies Pty Ltd
Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.
Backed By Leading Investment Groups and Family Offices
